liraglutide

Summary

Summary: An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.

Top Publications

  1. Courreges J, Vilsbøll T, Zdravkovic M, Le Thi T, Krarup T, Schmitz O, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med. 2008;25:1129-31 pubmed publisher
  2. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy. N Engl J Med. 2010;362:774-7 pubmed publisher
  3. Hallberg P, Schwan S, Melhus H. Liraglutide for weight loss in obese people. Lancet. 2010;375:551; author reply 552-3 pubmed publisher
  4. Wu X, Li S, Xue P, Li Y. Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAM. Exp Cell Res. 2017;360:281-291 pubmed publisher
    ..Thus in this paper, we investigated the effects of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, on murine MC3T3-E1 preosteoblasts proliferation and ..
  5. Suzuki S, Oura T, Takeuchi M, Boye K. Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies. Health Qual Life Outcomes. 2017;15:123 pubmed publisher
    ..75 mg (dulaglutide) once weekly; comparators were once-daily liraglutide (0...
  6. Hemmingsen B, Sonne D, Metzendorf M, Richter B. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017;5:CD012204 pubmed publisher
    ..One RCT of liraglutide contributed 85% of all participants. The duration of the intervention varied from 12 weeks to 160 weeks...
  7. Skolnik N, Jaffa F, Kalyani R, Johnson E, Shubrook J. Reducing CV risk in diabetes: An ADA update. J Fam Pract. 2017;66:300-308 pubmed
    ..This Q&A highlights changes to the ADA's 2017 Standards of Care to help you fine-tune your approach to patients who have, or are at risk for, atherosclerotic CV disease. ..
  8. Cyganek K, Koblik T, Kozek E, Wojcik M, Starzyk J, Malecki M. Liraglutide therapy in Prader-Willi syndrome. Diabet Med. 2011;28:755-6 pubmed publisher
  9. Millar P, Pathak N, Parthsarathy V, Bjourson A, O Kane M, Pathak V, et al. Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice. J Endocrinol. 2017;234:255-267 pubmed publisher
    ..actions of the sodium glucose cotransporter-2 inhibitor dapagliflozin in combination with the GLP-1 agonist liraglutide in dietary-induced diabetic mice...

More Information

Publications32

  1. Shi L, Ji Y, Jiang X, Zhou L, Xu Y, Li Y, et al. Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways. Cardiovasc Diabetol. 2015;14:18 pubmed publisher
    As a new anti-diabetic medicine, Liraglutide (LIRA), one of GLP-1 analogues, has been found to have an anti-atherosclerotic effect...
  2. Gilbert M, Marre M, Holst J, Garber A, Baeres F, Thomsen H, et al. COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES. Endocr Pract. 2016;22:406-11 pubmed publisher
    ..This subgroup analysis aimed to compare long-term effects of liraglutide and glimepiride on bone mineral density (BMD) in patients with type 2 diabetes...
  3. Edelman S. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists. J Fam Pract. 2017;66:S12-S16 pubmed
    Since 2005, four new GLP-1RAs (liraglutide, albiglutide, dulaglutide, and lixisenatide) and a once-weekly formulation of exenatide were approved for the treatment of persons with T2DM...
  4. Macut D, Bozic Antic I, Bjekić Macut J, Tziomalos K. MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease. Eur J Endocrinol. 2017;177:R145-R158 pubmed publisher
    ..b>Liraglutide use in obese PCOS has shown favorable effects on the predictors of liver fibrosis...
  5. Mann J, Ørsted D, Brown Frandsen K, Marso S, Poulter N, Rasmussen S, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377:839-848 pubmed publisher
    In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted ..
  6. Kramer C, Zinman B, Choi H, Connelly P, Retnakaran R. Impact of the Glucagon Assay When Assessing the Effect of Chronic Liraglutide Therapy on Glucagon Secretion. J Clin Endocrinol Metab. 2017;102:2729-2733 pubmed publisher
    Glucagon-like peptide-1 agonists acutely lower serum glucagon. However, in the Liraglutide and ?-Cell Repair (LIBRA) Trial, 48-week treatment with liraglutide yielded lower/unchanged fasting glucagon but, surprisingly, enhanced ..
  7. Sun H, Lu N, Luo X, Zhao L, Liu J. Liraglutide, the glucagon-like peptide-1 receptor agonist, has anabolic bone effects in diabetic Goto-Kakizaki rats. J Diabetes. 2015;7:584-8 pubmed publisher
  8. Larsen J, Vedtofte L, Jakobsen M, Jespersen H, Jakobsen M, Svensson C, et al. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2017;74:719-728 pubmed publisher
    ..Previous interventions designed to counteract antipsychotic-induced weight gain and cardiometabolic disturbances reported limited effects...
  9. Sassoon D, Tune J, Mather K, Noblet J, Eagleson M, Conteh A, et al. Glucagon-Like Peptide 1 Receptor Activation Augments Cardiac Output and Improves Cardiac Efficiency in Obese Swine After Myocardial Infarction. Diabetes. 2017;66:2230-2240 pubmed publisher
    ..Animals received subcutaneous injections of saline or liraglutide (0.005-0.015 mg/kg/day) for 30 days after ameroid placement...
  10. Briyal S, Shah S, Gulati A. Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia. Neuroscience. 2014;281:269-81 pubmed publisher
    Stroke is a leading cause of death and serious, long-term disability worldwide. We report that rats receiving liraglutide show markedly attenuated infarct volumes and neurological deficit following ischemic insult...
  11. Chamberlain J, Kalyani R, Leal S, Rhinehart A, Shubrook J, Skolnik N, et al. Treatment of Type 1 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. 2017;167:493-498 pubmed publisher
    ..Feedback from the larger clinical community informed revisions. This synopsis focuses on recommendations from the 2017 Standards of Care about monitoring and pharmacologic approaches to glycemic management for type 1 diabetes. ..
  12. Li M, Yang Y, Jiang D, Ying M, Wang Y, Zhao R. Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis. Medicine (Baltimore). 2017;96:e8161 pubmed publisher
    The aim of this systematic review was to evaluate the efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes and provide reference basis for rational use of clinical ..
  13. Baron H. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist. J Fam Pract. 2017;66:S17-S28 pubmed
    ..This article presents the rationale and data for combining a basal insulin with a GLP-1RA, including as fixed-ratio products...
  14. Chen J, Zhao H, Ma X, Zhang Y, Lu S, Wang Y, et al. GLP-1/GLP-1R Signaling in Regulation of Adipocyte Differentiation and Lipogenesis. Cell Physiol Biochem. 2017;42:1165-1176 pubmed publisher
    The aim of this study was to determine the direct role of liraglutide (LG) in adipogenesis and lipid metabolism...
  15. Myat A, Arri S, Bhatt D, Gersh B, Redwood S, Marber M. Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover study. Cardiovasc Diabetol. 2015;14:27 pubmed publisher
    ..The hypothesis being liraglutide, a subcutaneously injectable glucagon-like peptide-1 receptor agonist, is able to improve exercise ..
  16. Simo R, Hernandez C. GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?. Diabetes. 2017;66:1453-1460 pubmed publisher
    ..2 diabetes in 2008, the results of two outstanding clinical trials using GLP-1R agonists addressing this issue (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results-A Long Term Evaluation [LEADER] and ..
  17. Chudleigh R, Bain S. Cardiovascular safety of liraglutide for the treatment of type 2 diabetes. Expert Opin Drug Saf. 2017;16:627-635 pubmed publisher
    b>Liraglutide is a GLP-1 RA that is an option for treatment of T2DM. Typical of all new glucose-lowering agents, its CV safety profile is of great interest...
  18. . EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59:1121-40 pubmed publisher
  19. Marso S, Lindsey J, Stolker J, House J, Martinez Ravn G, Kennedy K, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res. 2011;8:237-40 pubmed publisher
    We assessed the cardiovascular safety of liraglutide, a glucagon-like peptide-1 receptor agonist, using existing clinical data...
  20. Secher A, Jelsing J, Baquero A, Hecksher Sørensen J, Cowley M, Dalbøge L, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124:4473-88 pubmed publisher
    b>Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2 diabetes. Besides lowering blood glucose, liraglutide also reduces body weight...
  21. Kondo M, Toyoda M, Kimura M, Ishida N, Fukagawa M. Favorable Effect on Blood Volume Control in Hemodialysis Patients with Type 2 Diabetes after Switching from Insulin Therapy to Liraglutide, a Human Glucagon-like Peptide-1 Analog--Results from a Pilot Study in Japan-. Tokai J Exp Clin Med. 2017;42:52-57 pubmed
    ..of five Japanese hemodialysis patients with type 2 diabetes mellitus (T2DM) who were switched from insulin to liraglutide, and the efficacy of the treatment, especially in terms of changes in interdialysis weight gain (IDWG)...
  22. Luconi M, Cantini G, Ceriello A, Mannucci E. Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip. Int J Cardiol. 2017;241:302-310 pubmed publisher
    ..drugs used in type 2 diabetes mellitus, namely glucagon-like peptide-1 receptor agonists (GLP-1RA), liraglutide and semaglutide, showed a reduction in cardiovascular events, which had not been observed in trials with other ..
  23. Manigault K, Thurston M. Liraglutide: A Glucagon-Like Peptide-1 Agonist for Chronic Weight Management. Consult Pharm. 2016;31:685-697 pubmed publisher
    To review the efficacy and safety of liraglutide 3.0 mg for weight loss. A literature search was performed using PubMed and MEDLINE from 2000 to 2016...